MAY 25, 2017 10:30 AM PDT

Open Targets Platform: mining gene and disease evidence for improved drug target selection.

Speaker

Abstract

Open Targets is a public-private partnership made up of four global leading institutions in the fields of pharmaceuticals, bioinformatics and genomics, GSK, EMBL-EBI, the Wellcome Trust Sanger Institute, and Biogen. We combine large-scale genomic experiments with objective statistical and computational techniques to identify and validate the causal links between targets, pathways and diseases. We have designed and developed the Open Targets Platform, a web application for data integration and visualisation, which supports both target- and disease-centric workflows. Our Platform enables biomedical researchers to discover and prioritise biological targets for new therapies. Targets may be a protein, protein complex or RNA molecule, and we integrate evidence through the target gene. Phenotypes and diseases are integrated through the Experimental Factor Ontology, so that we can include both Mendelian (rare) and common diseases and their phenotypes. We derive evidence of association between a target and a disease from multiple public domain resources, including germline and somatic genetics, known drugs, differential gene expression profiling, reaction pathways, murine genetic models and the scientific literature. We also provide an association score, which takes into account the observed frequency, the experiment confidence, and the likely strength of the effect of the target on the disease. By drawing on expertise in product and platform development including product testing, UX design and site development, we have created this comprehensive and robust data integration for access and visualisation. In addition, programmatic retrieval of data via REST services is also available as well as dumps of our entire datasets. In this talk, I will introduce the Open Targets Consortium and focus on our Open Targets Platform. I will demonstrate how the Platform can be used to visualise and interpret target and disease associations based on the different datasets available.


You May Also Like
MAY 25, 2017 10:30 AM PDT

Open Targets Platform: mining gene and disease evidence for improved drug target selection.



Loading Comments...